NCT04883437View on ClinicalTrials.gov

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

September 23, 2025

Study Completion Date

January 15, 2026

Conditions
Grade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaIndolent Non-Hodgkin LymphomaLymphoplasmacytic LymphomaLymphoproliferative DisorderMantle Cell LymphomaMarginal Zone Lymphoma
Interventions
DRUG

Acalabrutinib

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER